Grupo de Melanoma

Inicio | Investigación e innovación | Programas Científicos | Programa de Oncología Molecular | Grupo de Melanoma

«Este contenido se encuentra unicamente en inglés»

María S. Soengas
María S. Soengas Jefe de Grupo
T +34 917328000 (Ext 3680)


  • David Olmeda

Becarios Post-doctorales

  • Paula Pennacchi
  • Susana Frago

Becarios Pre-Doctorales

  • Xavier Catena
  • Daniela Carolina Cerezo
  • Marta Contreras
  • Cristina Tejedo

Técnicos de Laboratorio

  • Tonantzin Guadalupe Calvo
  • Estela Cañón

Melanomas are inherently aggressive cancers for which basic and translational research have significantly improved patient prognosis. Nevertheless, clinical responses are still incomplete. The long-term goals of our Group are to identify new progression biomarkers and therapeutic agents. Focusing on stress response programmes involving apoptosis, autophagy and endosome mobilisation, we have discovered lineage-specific oncogenes that define the melanoma ‘fingerprint’. Transcriptomic and proteomic analyses of the melanoma secretome have allowed us to define how tumour cells remodel the (lymp)angiogenic vasculature and avoid immune recognition. Moreover, we have generated a unique set of animal models for non-invasive imaging of melanoma progression in vivo. These systems have led to the validation of nanoparticle-based treatments which are being currently being tested in clinical trials. Our ultimate objective is to improve the management of patients with otherwise refractory metastatic melanomas..